CN Bio Innovations’ (CN Bio) Investigator Meeting entitled “Hepatitis B: New models pave the way to a cure” was held on Monday 10th November 2014 at the 65th AASLD Annual Meeting. The event, which was oversubscribed, focused on the need for new pre-clinical models for the study of hepatitis B and discovery of new therapeutics and biomarkers, and included presentations from Professor Mark Thursz, Professor of Hepatology at Imperial College and Head of the Section of Hepatology and Gastroenterology at St Mary’s Hospital, London, Professor Tim Block, Director of Drexel College of Medicine’s Institute for Biotechnology and Virology Research and Founder and President of the Hepatitis B Foundation, Dr Marcus Dorner, Non-Clinical Lecturer in Immunology at Imperial College, London, and Professor Mala Maini, Professor of Viral Immunology in the Division of Infection and Immunity at University College London. Leading academic researchers were joined in the audience by more than 40 participants representing 14 pharmaceutical companies, evidencing a strong commitment from industry in the search for a cure for Hepatitis B. Presentations from this event are now available at: https://www.cn-bio.com/media/aasld-investigator-meeting/. The potential role CN Bio’s Quantum-B® model of Hepatitis B could play in the search for new curative approaches was highlighted by Professor Block, Dr Dorner and Professor Maini. Recent research data from the company’s collaboration with Imperial College London was presented in an oral abstract session by Sann Nu Wai on Tuesday 11th November, a copy of which is available here
by CN Bio